F

Fennec Pharmaceuticals Inc
NASDAQ:FENC

Watchlist Manager
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Watchlist
Price: 7.54 USD -0.13%
Market Cap: 257.5m USD

Net Margin
Fennec Pharmaceuticals Inc

-17.9%
Current
-236%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-17.9%
=
Net Income
-6.9m
/
Revenue
38.8m

Net Margin Across Competitors

No Stocks Found

Fennec Pharmaceuticals Inc
Glance View

Market Cap
257.5m USD
Industry
Biotechnology

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

FENC Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-17.9%
=
Net Income
-6.9m
/
Revenue
38.8m
What is the Net Margin of Fennec Pharmaceuticals Inc?

Based on Fennec Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -17.9%.

Back to Top